Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions

Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions

Background: IgPro20 is the first approved subcutaneous immunoglobulin (SCIg) preparation for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Two different doses of the SCIg preparation were investigated in the pivotal PATH study. Real-world data, and particul...

Full description

Bibliographic Details
Main Authors:	Stefan Gingele, Moritz Koch, Anna Christina Saparilla, Gudrun M. Körner, Jarle von Hörsten, Marina Gingele, Tabea Seeliger, Franz Felix Konen, Martin W. Hümmert, Alexandra Neyazi, Martin Stangel, Thomas Skripuletz
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-04-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/17562864211009100

Similar Items

Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
by: Robert D. M. Hadden, et al.
Published: (2015-01-01)

Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome
by: Tabea Seeliger, et al.
Published: (2019-07-01)

Delayed Demyelination and Impaired Remyelination in Aged Mice in the Cuprizone Model
by: Stefan Gingele, et al.
Published: (2020-04-01)

Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP
by: Lars Kjøbsted Markvardsen, et al.
Published: (2019-05-01)

The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP
by: Richard K. Burt, et al.
Published: (2021-03-01)

Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned
by: Viktoria eGudi, et al.
Published: (2014-03-01)

Reiber’s Diagram for Kappa Free Light Chains: The New Standard for Assessing Intrathecal Synthesis?
by: Philipp Schwenkenbecher, et al.
Published: (2019-11-01)

Investigation of Oligoclonal IgG Bands in Tear Fluid of Multiple Sclerosis Patients
by: Martin W. Hümmert, et al.
Published: (2019-05-01)

Role of CD20+ T cells in multiple sclerosis: implications for treatment with ocrelizumab
by: Stefan Gingele, et al.
Published: (2020-01-01)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
by: Campbell Kaitryn, et al.
Published: (2010-06-01)

Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis
by: Philipp Schwenkenbecher, et al.
Published: (2019-03-01)

The Misdiagnosis of CIDP: A Review
by: Jeffrey A. Allen
Published: (2020-03-01)

Treatment Approaches for Atypical CIDP
by: Deepak Menon, et al.
Published: (2021-03-01)

Modelling business processes with links to ISO 9001
by: Gingele, Joachim
Published: (2001)

CIDP mimics: a case series
by: Orly Moshe-Lilie, et al.
Published: (2021-02-01)

Severe CIDP-MGUS responsive to Rituximab
by: Andreas Posa, et al.
Published: (2020-06-01)

IS NERVE BIOPSY USEFUL IN DIAGNOSIS OF CIDP?
by: Ioana Mindruta, et al.
Published: (2011-03-01)

Immunophenotyping of cerebrospinal fluid cells by Chipcytometry
by: Martin W. Hümmert, et al.
Published: (2018-05-01)

Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins
by: Martin Stangel
Published: (2008-09-01)

The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation
by: Franz Felix Konen, et al.
Published: (2020-03-01)

The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis
by: Philipp Schwenkenbecher, et al.
Published: (2018-11-01)

Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation
by: Martin W. Hümmert, et al.
Published: (2021-04-01)

Evidence of Oligoclonal Bands Does Not Exclude Non-Inflammatory Neurological Diseases
by: Katharina Pannewitz-Makaj, et al.
Published: (2021-12-01)

Fumaric Acids Do Not Directly Influence Gene Expression of Neuroprotective Factors in Highly Purified Rodent Astrocytes
by: Kaweh Pars, et al.
Published: (2019-09-01)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
by: Stefan Gingele, et al.
Published: (2018-12-01)

Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis Under Immunosuppression After Liver Transplantation
by: Franz Felix Konen, et al.
Published: (2019-09-01)

Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
by: Anna Kostera-Pruszczyk, et al.
Published: (2021-07-01)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
by: Philipp Scheuerlein, et al.
Published: (2018-07-01)

Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients
by: Diamantis Athanasopoulos, et al.
Published: (2021-05-01)

The economic burden of CIDP in the United States: A case-control study.
by: Victoria Divino, et al.
Published: (2018-01-01)

Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination.
by: Alon Abraham, et al.
Published: (2015-01-01)

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders
by: Min-Suk Yoon, et al.
Published: (2015-07-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Chronic Granulomatous Disease First Diagnosed in Adulthood Presenting With Spinal Cord Infection
by: Philipp Schwenkenbecher, et al.
Published: (2018-06-01)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
by: Martin Adriana, et al.
Published: (2012-11-01)

Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen
by: Stefan Gingele, et al.
Published: (2019-07-01)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
by: Martin Adriana, et al.
Published: (2012-11-01)

Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies
by: Verena I. Leussink, et al.
Published: (2016-07-01)

Conductive hearing loss in chronic inflammatory demyelinating polyneuropathy (CIDP): A case report
by: Mark A. Fadel, et al.
Published: (2018-12-01)